Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" or the "Company"), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence (AI)-based risk model with promising emerging therapies that may help prevent breast cancer in high-risk patients. BIO-Europe 2024 is scheduled for November 4-6, 2024, in Stockholm, Sweden. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

"I am honored to join Dr. Hall of the Karolinska Institute at BIO-Europe 2024 and discuss the potential for AI and endoxifen to transform the breast cancer treatment paradigm by identifying women at high risk of developing breast cancer who could potentially benefit from treatment to prevent the disease before it develops," said Steven Quay, M.D., Ph.D. "The focal point of the fireside chat will be the Stockholm Mammography Risk Stratified Trial or SMART study, which Dr. Hall's laboratory is leading and Atossa is supporting. This groundbreaking study is seeking to enroll 70,000 women to test an individualized, imaging-based screening model designed to identify women with the highest risk of developing breast cancer in the next two years. If the model is validated for therapeutic use, it could serve as the foundation for a future trial investigating (Z)-endoxifen in the breast cancer prevention setting."

Details of the fireside chat are as follows:

Event:	BIO-Europe 2024
Fireside Chat:	Atossa Therapeutics and the Karolinska Institute: The SMART study: A Unique Swedish American Collaboration to Prevent Breast Cancer
Date and Time	Monday, November 4th at 5:00 PM, CET
Location	Room K11, Stockholmsmässan

About Atossa Therapeutics

Atossa Therapeutics, Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit www.atossatherapeutics.com.

FORWARD LOOKING STATEMENTS
This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as "expect," "potential," "continue," "may," "will," "should," "could," "would," "seek," "intend," "plan," "estimate," "anticipate," "believe," "future," or other comparable words. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, such as data related to the (Z)-endoxifen program, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, and potential milestones and growth opportunities for the Company, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim and final clinical results; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to remain compliant with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

Contact:

Michael Parks
VP, Investor and Public Relations
484-356-7105
[email protected]

Public link

Please use the above public link if you want to share this noodl on another website.